Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy

4区 医学 Q1 Medicine Atherosclerosis. Supplements Pub Date : 2020-12-01 DOI:10.1016/j.atherosclerosissup.2021.01.005
Bernhard Föger , Catriona Jennings , Angela Pirillo , Lale Tokgözoğlu , Matteo Pirro , Alberico L. Catapano
{"title":"Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy","authors":"Bernhard Föger ,&nbsp;Catriona Jennings ,&nbsp;Angela Pirillo ,&nbsp;Lale Tokgözoğlu ,&nbsp;Matteo Pirro ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.005","DOIUrl":null,"url":null,"abstract":"<div><p>The availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-moderate hypercholesterolemia, which are not eligible for a pharmacological approach and are not far from the cholesterol target recommended for their risk category, functional foods or nutraceuticals may be considered as supplement to reduce their CV risk status. Of note, counseling and lifestyle intervention in people at moderate CV risk represents a major issue for both preventing a further risk increase and reducing the need for drugs. Studies on general populations have clearly indicated that lifestyle interventions translate into a clinical benefit, with reduction of the incidence of myocardial infarction and the risk of developing type 2 diabetes.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.005","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis. Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567568821000052","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

The availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-moderate hypercholesterolemia, which are not eligible for a pharmacological approach and are not far from the cholesterol target recommended for their risk category, functional foods or nutraceuticals may be considered as supplement to reduce their CV risk status. Of note, counseling and lifestyle intervention in people at moderate CV risk represents a major issue for both preventing a further risk increase and reducing the need for drugs. Studies on general populations have clearly indicated that lifestyle interventions translate into a clinical benefit, with reduction of the incidence of myocardial infarction and the risk of developing type 2 diabetes.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高胆固醇血症和心血管疾病:开始药物治疗前该做什么
有效降脂药物的可用性大大降低了心血管疾病(CVD)的发病率和死亡率。尽管如此,心血管疾病仍然是导致死亡和残疾的主要原因;因此,需要努力预防这种疾病,因为减少既定的心血管危险因素可能会减缓或预防心血管事件的发生。目前的指南建议对所有心血管风险类别的人都采取更健康的生活方式,因为它可能对几个风险因素产生有益的影响;对于低中度高胆固醇血症患者,不适合采用药理学方法,且距离其风险类别推荐的胆固醇目标不远,可考虑使用功能性食品或营养保健品作为补充,以降低其心血管风险状态。值得注意的是,对中度心血管风险人群进行咨询和生活方式干预是预防进一步风险增加和减少药物需求的主要问题。对一般人群的研究清楚地表明,生活方式干预可以转化为临床益处,可以降低心肌梗死的发病率和患2型糖尿病的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Atherosclerosis. Supplements
Atherosclerosis. Supplements 医学-外周血管病
CiteScore
4.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations.
期刊最新文献
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives Lipid Clinics Network. Rationale and design of the EAS global project Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool ‘Diet and lifestyle’ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1